Galmed Pharmaceuticals (GLMD) Competitors $3.34 -0.16 (-4.57%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GLMD vs. ANL, CLRB, ALXO, VRCA, SPRO, CTXR, RAPT, ZIVO, OMGA, and ONCOShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Adlai Nortye (ANL), Cellectar Biosciences (CLRB), ALX Oncology (ALXO), Verrica Pharmaceuticals (VRCA), Spero Therapeutics (SPRO), Citius Pharmaceuticals (CTXR), RAPT Therapeutics (RAPT), ZIVO Bioscience (ZIVO), Omega Therapeutics (OMGA), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Adlai Nortye Cellectar Biosciences ALX Oncology Verrica Pharmaceuticals Spero Therapeutics Citius Pharmaceuticals RAPT Therapeutics ZIVO Bioscience Omega Therapeutics Onconetix Adlai Nortye (NASDAQ:ANL) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Do analysts rate ANL or GLMD? Adlai Nortye presently has a consensus target price of $9.00, indicating a potential upside of 350.00%. Given Adlai Nortye's higher probable upside, research analysts plainly believe Adlai Nortye is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Galmed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is ANL or GLMD more profitable? Adlai Nortye's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Galmed Pharmaceuticals N/A -27.06%-23.47% Do insiders and institutionals have more ownership in ANL or GLMD? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ANL or GLMD? Galmed Pharmaceuticals received 435 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdlai NortyeOutperform Votes7100.00% Underperform VotesNo VotesGalmed PharmaceuticalsOutperform Votes44263.69% Underperform Votes25236.31% Which has preferable valuation and earnings, ANL or GLMD? Galmed Pharmaceuticals has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M14.76-$104.87MN/AN/AGalmed PharmaceuticalsN/AN/A-$6.91M-$2.40-1.39 Does the media favor ANL or GLMD? In the previous week, Adlai Nortye and Adlai Nortye both had 2 articles in the media. Adlai Nortye's average media sentiment score of 1.58 beat Galmed Pharmaceuticals' score of 0.84 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAdlai Nortye beats Galmed Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.85M$7.12B$5.36B$8.41BDividend YieldN/A8.77%5.22%4.20%P/E Ratio-0.1916.06131.9317.57Price / SalesN/A258.281,440.1578.36Price / CashN/A50.1639.0633.56Price / Book0.105.674.744.57Net Income-$6.91M$151.16M$115.43M$225.42M7 Day Performance-17.12%-1.80%-0.86%-0.61%1 Month Performance-51.31%5.92%3.61%1.50%1 Year Performance-26.75%39.97%38.90%32.94% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals2.0045 of 5 stars$3.34-4.6%N/A-20.0%$16.85MN/A-0.1920Short Interest ↓News CoverageANLAdlai Nortye3.225 of 5 stars$2.00-2.9%$9.00+350.0%-76.1%$73.80M$5M0.00127Positive NewsHigh Trading VolumeCLRBCellectar Biosciences2.8793 of 5 stars$2.05flat$21.00+924.4%-14.6%$73.49MN/A-0.6710Short Interest ↓ALXOALX Oncology3.3654 of 5 stars$1.40-4.1%$12.50+792.9%-79.9%$72.94MN/A-0.3840Positive NewsVRCAVerrica Pharmaceuticals4.1951 of 5 stars$1.68+7.7%$11.40+578.6%-54.4%$71.27M$13.91M-0.8940Short Interest ↑SPROSpero Therapeutics4.7378 of 5 stars$1.31+1.6%$7.00+434.4%+25.2%$70.72M$105.43M3.9746News CoverageGap DownHigh Trading VolumeCTXRCitius Pharmaceuticals3.217 of 5 stars$0.39+5.4%$4.00+924.6%-46.0%$70.54MN/A-1.6320Positive NewsRAPTRAPT Therapeutics4.0496 of 5 stars$2.00+3.6%$18.17+808.3%-81.0%$69.81M$1.53M-0.6480ZIVOZIVO BioscienceN/A$19.95flatN/A+640.0%$69.63M$30,000.00-3.7910Positive NewsOMGAOmega Therapeutics1.9655 of 5 stars$1.24-2.4%$10.20+722.6%-14.2%$68.39M$3.09M-0.87120ONCOOnconetix1.5267 of 5 stars$3.04-15.1%N/AN/A$67.88M$1.46M0.0012Positive NewsGap Down Related Companies and Tools Related Companies ANL Competitors CLRB Competitors ALXO Competitors VRCA Competitors SPRO Competitors CTXR Competitors RAPT Competitors ZIVO Competitors OMGA Competitors ONCO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLMD) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.